However, in HOXA-expressing AML, such as AML with NPM1 or MLL gene mutations, RIPK3 signaling is activated, which promotes such AML development by repressing the differentiation of leukemic cells via inhibition of JAK1-STAT1 signaling (Xin et al., 2016b). This evidence concerns the gene RIPK3 and acute myeloid leukemia.